TOPNIVO: A safety study of nivolumab in patients with recurrent and/or metastatic platinum-refractory squamous cell carcinoma of the head and neck (R/M SCCHN): First results on behalf of the UNICANCER Head&Neck Group and the GORTEC

Affiliation auteurs!!!! Error affiliation !!!!
TitreTOPNIVO: A safety study of nivolumab in patients with recurrent and/or metastatic platinum-refractory squamous cell carcinoma of the head and neck (R/M SCCHN): First results on behalf of the UNICANCER Head&Neck Group and the GORTEC
Type de publicationJournal Article
Year of Publication2018
AuteursEven C., Daste A., Saada-Bouzid E., Fayette J., Kaminsky-Forrett M-C., Zanetta S., Prevost A., Lefebvre G., Borel C., Cupissol D., Huguet F., Delord J-P., N. Rotllan B, Delaye J., Jallut I., Vintonenko N., Bourhis J., Guigay J., Texier M., Auperin A.
JournalANNALS OF ONCOLOGY
Volume29
Pagination380
Date PublishedOCT
Type of ArticleMeeting Abstract
ISSN0923-7534